Entities / Entity
lifileucel.
experimental autologous cell therapy for metastatic melanoma
- Reports this week
- 0
- Active events
- 0
- Connections
- 4
What's happening
Gone quiet
No new reports in 90+ days-
Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.Some support4 reports1 development inside
-
Iovance Biotherapeutics received conditional approval for its drug lifileucel, expanding its potential market reach.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 4, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Iovance Biotherapeutics Structural
Iovance Biotherapeutics develops and delivers the lifileucel therapy, whose sales and approval drive the company's revenue and market reach.